UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1518) 1518
Newsletter (125) 125
Newspaper Article (74) 74
Book Chapter (37) 37
Magazine Article (13) 13
Transcript (7) 7
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ipilimumab (1587) 1587
science & technology (1185) 1185
life sciences & biomedicine (1155) 1155
humans (1048) 1048
melanoma (858) 858
immunotherapy (807) 807
oncology (784) 784
melanoma - drug therapy (538) 538
cancer (516) 516
male (496) 496
care and treatment (450) 450
metastasis (448) 448
antibodies, monoclonal - therapeutic use (426) 426
female (415) 415
middle aged (397) 397
aged (340) 340
nivolumab (321) 321
antibodies, monoclonal - adverse effects (310) 310
drug therapy (288) 288
patients (288) 288
skin neoplasms - drug therapy (275) 275
antibodies, monoclonal - administration & dosage (268) 268
melanoma - pathology (266) 266
adult (248) 248
research (245) 245
immunology (239) 239
cancer therapies (235) 235
treatment outcome (235) 235
chemotherapy (229) 229
clinical trials (220) 220
antineoplastic agents - therapeutic use (208) 208
pembrolizumab (192) 192
melanoma - immunology (188) 188
antineoplastic combined chemotherapy protocols - therapeutic use (185) 185
skin neoplasms - pathology (182) 182
tumors (181) 181
ctla-4 antigen - antagonists & inhibitors (177) 177
dosage and administration (169) 169
immunotherapy - methods (159) 159
health aspects (158) 158
antigens (156) 156
lymphocytes (150) 150
aged, 80 and over (147) 147
ctla-4 (146) 146
immune checkpoint (142) 142
monoclonal antibodies (142) 142
complications and side effects (141) 141
programmed cell death 1 receptor - antagonists & inhibitors (137) 137
antineoplastic agents - adverse effects (136) 136
cytotoxicity (136) 136
ipilimumab - administration & dosage (136) 136
medical research (136) 136
melanoma - therapy (135) 135
melanoma - secondary (132) 132
metastases (132) 132
ipilimumab - adverse effects (131) 131
medicine & public health (130) 130
analysis (129) 129
ctla-4 antigen - immunology (129) 129
neoplasms. tumors. oncology. including cancer and carcinogens (125) 125
lung cancer (124) 124
t cells (122) 122
medicine, research & experimental (119) 119
research & experimental medicine (119) 119
dermatology (118) 118
neoplasm metastasis (118) 118
animals (114) 114
ipilimumab - therapeutic use (114) 114
medical prognosis (112) 112
neoplasm staging (111) 111
melanoma - mortality (110) 110
usage (109) 109
immune system (107) 107
skin cancer (106) 106
clinical trials as topic (104) 104
antineoplastic agents, immunological - adverse effects (102) 102
apoptosis (102) 102
prognosis (102) 102
mutation (101) 101
antineoplastic combined chemotherapy protocols - adverse effects (100) 100
case report (97) 97
pharmacology & pharmacy (97) 97
development and progression (96) 96
toxicity (95) 95
fda approval (93) 93
antineoplastic agents, immunological - therapeutic use (91) 91
retrospective studies (91) 91
antibodies (89) 89
pd-1 (89) 89
vemurafenib (89) 89
patient outcomes (88) 88
disease-free survival (85) 85
review (85) 85
hematology, oncology and palliative medicine (84) 84
biomarkers (83) 83
neoplasms - drug therapy (83) 83
abridged index medicus (82) 82
lymphocytes t (82) 82
skin neoplasms - immunology (82) 82
medicine, experimental (81) 81
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1755) 1755
French (10) 10
German (9) 9
Japanese (5) 5
Russian (3) 3
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Hebrew (1) 1
Norwegian (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue S11, pp. 2130 - 2142
Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration... 
neoantigen | targeted therapy | B‐Raf proto‐oncogene serine/threonine kinase (BRAF) | catenin‐β 1 (CTNNB1) | immunotherapy | combination therapy | melanoma | phosphatase and tensin homolog (PTEN) | neuroblastoma rat sarcoma viral oncogene homolog (NRAS) | guanosine‐triphosphate guanyltransferase (GTPase) | personalized medicine | catenin-β 1 (CTNNB1) | B-Raf proto-oncogene serine/threonine kinase (BRAF) | guanosine-triphosphate guanyltransferase (GTPase) | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Tumor Escape - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Ipilimumab | Wnt Signaling Pathway - immunology | Oximes - administration & dosage | Imidazoles - administration & dosage | Drug Resistance, Neoplasm | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Indoles - administration & dosage | MAP Kinase Kinase 1 - genetics | Pyridones - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | PTEN Phosphohydrolase - immunology | Melanoma - genetics | Immunotherapy | Tumor Escape - immunology | MAP Kinase Kinase 1 - antagonists & inhibitors | PTEN Phosphohydrolase - genetics | Skin Neoplasms - immunology | Membrane Proteins - genetics | GTP Phosphohydrolases - immunology | Membrane Proteins - immunology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Wnt Signaling Pathway - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Nivolumab | Proto-Oncogene Proteins B-raf - immunology | Skin Neoplasms - genetics | Pyrimidinones - administration & dosage | Mutation | CTLA-4 Antigen - antagonists & inhibitors | Sulfonamides - administration & dosage | Medical research | Translation | Immune response | Melanoma | Clinical trials | Patients | Immunity | Disease resistance | Alterations | Molecular modelling | Correlation analysis | Biomarkers | Cancer | Immune system | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article
Clinical cancer research, ISSN 1078-0432, 04/2018, Volume 24, Issue 8, pp. 1805 - 1815
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 12/2017, Volume 35, Issue 34, pp. 3807 - 3814
Journal Article